Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNexus Gene LabBGLC +1.19%58 PB Ratio is 0.51 as of Jul. 16, 2026, which is 84% below its 10-year median of 3.16. GuruFocus rates BGLC with a GF Score™ of 58/100 and a GF Value™ of $2.17 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,576 Chemicals companies, BioNexus Gene Lab ranks better than 91.12% on this metric.
BioNexus Gene Lab Corp stock PB Ratio (=0.5) is close to 1-year low of 0.5.
The historical rank and industry rank for BioNexus Gene Lab's PB Ratio or its related term are showing as below:
BGLC'
s PB Ratio Range Over the Past 10 Years
Min: 0.44 Med: 3.16 Max: 301.93
Current: 0.51
During the past 8 years, BioNexus Gene Lab's highest PB Ratio was 301.93. The lowest was 0.44. And the median was 3.16.
BGLC's PB Ratio is ranked better than 91.12% of 1576
companies
in the Chemicals industry
Industry Median: 1.7
vs BGLC: 0.51
During the past 12 months, BioNexus Gene Lab's average Book Value Per Share Growth Rate was -22.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -8.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -4.00% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of BioNexus Gene Lab was 52.00% per year. The lowest was -8.20% per year. And the median was 5.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
BioNexus Gene Lab PB Ratio Related Terms
BioNexus Gene Lab PB Ratio Historical Data
* Premium members only.
The historical data trend for BioNexus Gene Lab's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, BioNexus Gene Lab's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab PB Ratio vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's PB Ratio distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
BioNexus Gene Lab (BGLC) has a PB Ratio of 0.51 as of Jul. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioNexus Gene Lab and its competitors. This is 84% below median its historical median of 3.16. Over the past decade, BioNexus Gene Lab's PB Ratio has ranged from 0.44 to 301.93. According to the industry distribution chart, BioNexus Gene Lab ranks #140 out of 1576 companies in the Chemicals industry, placing it in the top 8.9%.
Is BioNexus Gene Lab's PB Ratio too high?
BioNexus Gene Lab's current PB Ratio of 0.51 is 84% below median its 10-year median of 3.16. Over the past 10 years, this metric has ranged from a low of 0.44 to a high of 301.93. The Chemicals industry median PB Ratio is 1.70. BioNexus Gene Lab's value of 0.51 is 70% below this industry median. Based on the distribution chart, BioNexus Gene Lab ranks #140 out of 1576 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, BioNexus Gene Lab has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's PB Ratio compare to QGAI and VYST?
According to the Chemicals industry distribution chart, BioNexus Gene Lab ranks #140 out of 1576 companies for PB Ratio. This places BioNexus Gene Lab in the top 9% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.70. BioNexus Gene Lab's value of 0.51 is 70% below this benchmark. Historically, BioNexus Gene Lab's own PB Ratio has ranged from 0.44 to 301.93 over the past decade. While the company's 10-year median is 3.16 vs. the industry median of 1.70, BioNexus Gene Lab has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Chemicals company?
The median PB Ratio among Chemicals companies is 1.70, based on 1,576 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioNexus Gene Lab's current PB Ratio of 0.51 is 70% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioNexus Gene Lab and its competitors. For the Chemicals industry, the median PB Ratio is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNexus Gene Lab's current PB Ratio is 0.51, which is 84% below median its own 10-year median of 3.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.17, compared to a current price of $1.70 — trading 21.7% below its estimated fair value. The current PB Ratio is 0.51, which is 84% below median its 10-year median of 3.16 and 70% below the Chemicals industry median of 1.70. BioNexus Gene Lab's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current PB Ratio is 0.51 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be undervalued.
The current stock price of $1.70 is trading 21.7% below its estimated GF Value™ of $2.17.
GuruFocus considers BioNexus Gene Lab to be Modestly Undervalued.
Key valuation signals for BGLC:
PB Ratio: 0.51 (84% below median its 10-year median of 3.16)
GF Value™: $2.17 vs. price of $1.70 (21.7% below fair value)
Industry Position: 70% below the Chemicals median (#140 of 1576)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
58GF Score
Get the complete analysis for BGLC
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
